| Dr Christopher Calvin Rife, MD | |
|
4545 R St, #100, Lincoln, NE 68503-3799 | |
| (402) 465-4545 | |
| (402) 465-9011 |
| Full Name | Dr Christopher Calvin Rife |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 16 Years |
| Location | 4545 R St, Lincoln, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699935536 | NPI | - | NPPES |
| 47071768613 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 28484 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bryan Medical Center | Lincoln, NE | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Chi Health St. Elizabeth | Lincoln, NE | Hospital |
| Beatrice Community Hospital & Health Center, Inc | Beatrice, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastroenterology Specialties Pc | 5991696775 | 45 |
News Archive
Researchers at the Thorax Centrum Twente of Medisch Spectrum Twente and the University of Twente have recently completed their fourth major study into the application of drug-eluting stents during percutaneous coronary intervention.
Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel.
Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers.
Human papillomavirus (HPV) can infect the mouth and throat to cause cancers of the oropharynx. A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, has found that having more than 10 prior oral sex partners was associated with a 4.3-times greater likelihood of having HPV-related oropharyngeal cancer.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
› Verified 6 days ago
| Entity Name | Gastroenterology Specialties Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083747380 PECOS PAC ID: 5991696775 Enrollment ID: O20040322001318 |
News Archive
Researchers at the Thorax Centrum Twente of Medisch Spectrum Twente and the University of Twente have recently completed their fourth major study into the application of drug-eluting stents during percutaneous coronary intervention.
Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel.
Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers.
Human papillomavirus (HPV) can infect the mouth and throat to cause cancers of the oropharynx. A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, has found that having more than 10 prior oral sex partners was associated with a 4.3-times greater likelihood of having HPV-related oropharyngeal cancer.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Christopher Calvin Rife, MD 4545 R St, #100, Lincoln, NE 68503-3799 Ph: (402) 465-4545 | Dr Christopher Calvin Rife, MD 4545 R St, #100, Lincoln, NE 68503-3799 Ph: (402) 465-4545 |
News Archive
Researchers at the Thorax Centrum Twente of Medisch Spectrum Twente and the University of Twente have recently completed their fourth major study into the application of drug-eluting stents during percutaneous coronary intervention.
Yet another exciting breakthrough took place yesterday in the advancement and development of the ARTIFICIAL PANCREAS by specialists at Schneider Children's Medical Center of Israel.
Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers.
Human papillomavirus (HPV) can infect the mouth and throat to cause cancers of the oropharynx. A new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society, has found that having more than 10 prior oral sex partners was associated with a 4.3-times greater likelihood of having HPV-related oropharyngeal cancer.
ev3 Inc., a global endovascular device company, today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the Pipeline Embolization Device for treatment of large, giant and wide-necked cerebral aneurysms. The FDA's action means that the PMA application was sufficiently complete and ready for substantive review. The filing date for regulatory purposes is May 18, 2010, the date the FDA received ev3's PMA submission.
› Verified 6 days ago
Ted M Triggs, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 555 S 70th St, Lincoln, NE 68510 Phone: 402-219-8747 Fax: 402-219-8748 | |
Joseph L Kummer, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1600 S 48th St, Suite 600, Lincoln, NE 68506 Phone: 402-483-3333 Fax: 402-483-3297 | |
Brenda Kay Bell, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1919 S 40th, Ste 207, Lincoln, NE 68506 Phone: 402-489-3383 Fax: 402-489-3789 | |
Scott Allen Heasty, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2300 S 16th St, Lincoln, NE 68502 Phone: 402-481-4780 Fax: 402-481-5377 | |
Scott Charles Rasmussen, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3901 Pine Lake Rd, Suite 220, Lincoln, NE 68516 Phone: 402-421-3240 Fax: 402-423-0739 | |
Jeffrey E Jarrett, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1500 S 48th St, Suite 800, Lincoln, NE 68506 Phone: 402-483-8600 Fax: 402-483-8689 | |
Tracy L Slocum Farritor, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 555 S 70th St, Lincoln, NE 68510 Phone: 402-219-8747 Fax: 402-219-8748 |